Roche and UCLA Stem Cell Researchers Agreement
An agreement between UCLA and Roche (SIX: RO, ROG; OTCQX: RHHBY) will provide stem cell and cancer researchers with leading-edge technologies that will drive research capabilities and further the understanding of complex disease.
- The technologies, including the latest generation microarray systems from Roche NimbleGen, high-throughput screening instruments, genetic expression profilers and exome sequencing technologies will provide scientists with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA and UCLA’s Jonsson Comprehensive Cancer Center with valuable technology directly from Roche’s research and development pipeline;
- Discoveries made by UCLA scientists while working with the technologies will help provide Roche scientists with insight on academic research and can be used to refine Roche operations or develop new applications for the equipment.
The Bottom Line: Under the agreement, Roche will also provide UCLA with advanced reagent, technologies and bioinformatics support to be used in the pursuit of discovering new predictive biomarkers, which will be used as targets for future therapeutics and diagnostics for a host of diseases. The agreement opens the door for UCLA and Roche scientists to work collaboratively with an initial focus on developing even more effective technologies for academic and commercial use. Future developments, based on these technologies, could lead to clinical trials of promising diagnostics and therapeutics. By working together at an early stage, Roche and UCLA can optimize the technologies and provide the necessary support to improve detection and analysis, and ultimately, the success rate of biomarker discovery.
